FDA makes historic ruling on biosimilar insulin

Patients taking Sanofi's long-acting insulin Lantus can now access Mylan's copy drug Semglee.

Photo: Andrew Kelly/REUTERS / X02844

On Thursday evening, the US Food and Drug Administration (FDA) ruled that a biosimilar drug is interchangeable with the original. It is the first time ever that the agency has done this.

For patients using Sanofi's long-acting insulin Lantus, this means that they will now be able to get Mylan's product Semglee from their pharmacist, without having a doctor's prescription for that specific drug.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs